Emergence of EGFR G724S After Progression on Osimertinib Responded to Afatinib Monotherapy

J Thorac Oncol. 2020 Mar;15(3):e36-e37. doi: 10.1016/j.jtho.2019.09.198.

Authors

Wenfeng Fang¹, Yihua Huang¹, Jiadi Gan¹, Qiufan Zheng¹, Li Zhang²

Affiliations

¹ Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.
² Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China. Electronic address: zhangli6@mail.sysu.edu.cn.

PMID: 32093857
DOI: 10.1016/j.jtho.2019.09.198

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Acrylamides
Afatinib / therapeutic use
Aniline Compounds
ErbB Receptors / genetics
Humans
Lung Neoplasms* / drug therapy
Mutation
Protein Kinase Inhibitors / therapeutic use

Substances

Acrylamides
Aniline Compounds
Protein Kinase Inhibitors
osimertinib
Afatinib
EGFR protein, human
ErbB Receptors